RE:Piper Sandler covers now LMNL: price target 22$Stups, you copy pasted the same thing four times. Meds bud, meds.
Has this analyst done any DD? Talking about their expertise in small molecules when all they have done is phase 1 dosing with fez. Nothing else commercialized and they fired lead researchers last year.
$22 ROF Check 5 year chart you will be amazed.
realstocky wrote: Liminal BioSciences initiated with an Overweight at Piper Sandler Piper Sandler analyst Yasmeen Rahimi initiated coverage of Liminal BioSciences with an Overweight rating and $22 price target. The company's core expertise is in the development of small molecules targeting fibrotic diseases with an iron focus on expansion of fezagepras for the treatment of fibrotic diseases, Rahimi tells investors in a research note. The analyst believes Liminal's valuation has been "significantly repressed" with a $120M market capitalization.
Read more at:
https://thefly.com/n.php?id=3216265
if u missed it:
https://thefly.com/landingPageNews.php?id=3216265&headline=LMNL-Liminal-BioSciences-initiated-with-an-Overweight-at-Piper-Sandler Liminal BioSciences initiated with an Overweight at Piper Sandler Piper Sandler analyst Yasmeen Rahimi initiated coverage of Liminal BioSciences with an Overweight rating and $22 price target. The company's core expertise is in the development of small molecules targeting fibrotic diseases with an iron focus on expansion of fezagepras for the treatment of fibrotic diseases, Rahimi tells investors in a research note. The analyst believes Liminal's valuation has been "significantly repressed" with a $120M market capitalization.
Read more at:
https://thefly.com/n.php?id=3216265
Liminal BioSciences initiated with an Overweight at Piper Sandler Piper Sandler analyst Yasmeen Rahimi initiated coverage of Liminal BioSciences with an Overweight rating and $22 price target. The company's core expertise is in the development of small molecules targeting fibrotic diseases with an iron focus on expansion of fezagepras for the treatment of fibrotic diseases, Rahimi tells investors in a research note. The analyst believes Liminal's valuation has been "significantly repressed" with a $120M market capitalization.
Read more at:
https://thefly.com/n.php?id=3216265
Liminal BioSciences initiated with an Overweight at Piper Sandler Piper Sandler analyst Yasmeen Rahimi initiated coverage of Liminal BioSciences with an Overweight rating and $22 price target. The company's core expertise is in the development of small molecules targeting fibrotic diseases with an iron focus on expansion of fezagepras for the treatment of fibrotic diseases, Rahimi tells investors in a research note. The analyst believes Liminal's valuation has been "significantly repressed" with a $120M market capitalization.
Read more at:
https://thefly.com/n.php?id=3216265